Abstracts tagged "guidelines and treatment"

Abstract Number: 861 • 2013 ACR/ARHP Annual Meeting
Many Gout Patients Treated By Rheumatologists Do Not Meet Established Treatment Goals Despite Long-Term Urate Lowering Therapy: Results Of a Gout Patient Encounter Survey
Max I. Hamburger¹, Michael H. Pillinger², Robert Sederman³ and Gary Fernandez⁴, ¹Rheumatology Associates, Melville, NY, ²NYU School of Medicine, Division of Rheumatology, New York, NY, ³C1 Consulting, LLC, Summit, NJ, ⁴Market Research, Savient Pharmaceuticals, Bridgewater, NJ
Background/Purpose: In Oct 2012, the ACR published guidelines for the management of gout. These guidelines recommend pharmacologic treatment that results in a sufficient lowering of…
Abstract Number: 839 • 2013 ACR/ARHP Annual Meeting
A Paradigm Change for Treatment Strategies for Fibromyalgia Syndrome Reflected By Recommendations of Recent Evidence-Based Interdisciplinary Guidelines Developed Independently in Three Countries
Jacob N. Ablin¹, Dan Buskila², Howard Amital³, Mary-Ann Fitzcharles⁴, Yoram Shir⁵, Peter Henningsen⁶ and Winfried Häuser⁷, ¹Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Ben-Gurion University, Beer-Sheva, Israel, ³Department of Medicine B, Center for Autoimmune Diseases, Sheba Medical Center, Tel-hashomer, Israel, ⁴Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ⁵Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ⁶Department Internal Medicine I, Klinikum Saarbrücken, Saarbrücken, Germany, ⁷Klinikum Saarbrücken, Saarbrücken, Germany
Background/Purpose: Although the ideal treatment for fibromyalgia (FM) remains elusive, the medical community requires direction in the care of these patients. The literature however abounds…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].